BiotechTube
Century Therapeutics

Century Therapeutics

IPSC
Philadelphia, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

IPSC · Stock Price

USD 2.31+1.77 (+330.17%)
Market Cap: $405.8M

Historical price data

Overview

Century Therapeutics is a clinical-stage biotechnology company developing allogeneic, iPSC-derived cell therapies for oncology and autoimmunity. Its core strategy is to utilize a renewable master iPSC bank, combined with precision genetic engineering, to create standardized, scalable, and readily available therapeutic products. Key achievements include advancing its lead CNTY-101 program into Phase 1 trials for B-cell malignancies and securing strategic collaborations with Bristol Myers Squibb and Bayer. The company's long-term vision is to establish iPSC-derived cell therapies as a mainstream, accessible treatment modality.

OncologyAutoimmune Diseases

Technology Platform

A proprietary platform that creates allogeneic cell therapies from a clonal master induced pluripotent stem cell (iPSC) bank, engineered with multiple precision gene edits to enhance potency, persistence, and immune evasion for scalable, 'off-the-shelf' manufacturing.

Opportunities

Validating its iPSC platform in the clinic could unlock a pipeline of standardized, scalable 'off-the-shelf' cell therapies for large oncology and autoimmune markets.
Strategic partnerships with Bristol Myers Squibb and Bayer provide significant funding, validation, and potential future milestone payments and royalties.
Success could position Century as a leader in the industrialization of cell therapy manufacturing.

Risk Factors

The company faces significant clinical risk as its lead candidate, CNTY-101, is in early-stage trials; failure would impact the entire platform.
The allogeneic approach carries the inherent risk of host immune rejection, potentially limiting product durability.
Intense competition in the cell therapy space and the technical complexity of scaling iPSC manufacturing present additional hurdles.

Competitive Landscape

Century competes directly with other allogeneic cell therapy developers like Fate Therapeutics (iPSC-NK), Allogene Therapeutics (alloCAR-T), and Precision BioSciences. It must also match the efficacy benchmarks set by commercial autologous CAR-T leaders (Gilead/Kite, BMS). Its differentiation lies in its clonal master iPSC bank, multi-edit engineering strategy, and strategic pharma partnerships.

More companies in United States →